Now available STOBOCLO®

STOBOCLO® (denosumab-bmwo) is biosimilar to PROLIA® (denosumab). 
STOBOCLO injection, for subcutaneous use, is a RANK ligand (RANKL) inhibitor indicated for treatment:

• of postmenopausal women with osteoporosis at high risk for fracture.
• to increase bone mass in men with osteoporosis at high risk for fracture.
• of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. 
• to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer.
• to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

View full prescribing information.